Clinical Trial Update: Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating nintedanib effects on extracellular matrix turnover biomarkers in idiopathic pulmonary fibrosis with limited forced vital capacity impa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Nintedanib (nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Idiopathic Pulmonary Fibrosis | Phase 4 | Status: COMPLETED | Results posted: 2019-08-06